Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients

There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 66; no. 1; p. e0163021
Main Authors Yamamuro, Ryosuke, Kimura, Muneyoshi, Asano-Mori, Yuki, Abe, Masahiro, Nakamura, Shigeki, Umeyama, Takashi, Yamagoe, Satoshi, Miyazaki, Yoshitsugu, Ogura, Sho, Sakoh, Takashi, Mitsuki, Takashi, Yamaguchi, Kyosuke, Yuasa, Mitsuhiro, Kaji, Daisuke, Kageyama, Kosei, Nishida, Aya, Taya, Yuki, Ishiwata, Kazuya, Takagi, Shinsuke, Yamamoto, Hisashi, Yamamoto, Go, Uchida, Naoyuki, Wake, Atsushi, Taniguchi, Shuichi, Araoka, Hideki
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 18.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus , and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus , A. felis , A. viridinutans , A. nidulans , and A. calidoustus . In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.
AbstractList There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus, A. felis, A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.
There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus , and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus , A. felis , A. viridinutans , A. nidulans , and A. calidoustus . In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.
There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, , , A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.
There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus, A. felis, A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus, A. felis, A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.
There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus , and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus , A. felis , A. viridinutans , A. nidulans , and A. calidoustus . In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.
Author Asano-Mori, Yuki
Miyazaki, Yoshitsugu
Yuasa, Mitsuhiro
Kaji, Daisuke
Yamamuro, Ryosuke
Takagi, Shinsuke
Umeyama, Takashi
Abe, Masahiro
Yamamoto, Hisashi
Taya, Yuki
Ishiwata, Kazuya
Araoka, Hideki
Nishida, Aya
Uchida, Naoyuki
Ogura, Sho
Yamamoto, Go
Yamagoe, Satoshi
Wake, Atsushi
Mitsuki, Takashi
Kageyama, Kosei
Taniguchi, Shuichi
Nakamura, Shigeki
Yamaguchi, Kyosuke
Sakoh, Takashi
Kimura, Muneyoshi
Author_xml – sequence: 1
  givenname: Ryosuke
  orcidid: 0000-0002-3987-9118
  surname: Yamamuro
  fullname: Yamamuro, Ryosuke
  organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
– sequence: 2
  givenname: Muneyoshi
  orcidid: 0000-0003-4461-1500
  surname: Kimura
  fullname: Kimura, Muneyoshi
  organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
– sequence: 3
  givenname: Yuki
  surname: Asano-Mori
  fullname: Asano-Mori, Yuki
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 4
  givenname: Masahiro
  surname: Abe
  fullname: Abe, Masahiro
  organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan
– sequence: 5
  givenname: Shigeki
  surname: Nakamura
  fullname: Nakamura, Shigeki
  organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan
– sequence: 6
  givenname: Takashi
  orcidid: 0000-0002-6635-4288
  surname: Umeyama
  fullname: Umeyama, Takashi
  organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan
– sequence: 7
  givenname: Satoshi
  surname: Yamagoe
  fullname: Yamagoe, Satoshi
  organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan
– sequence: 8
  givenname: Yoshitsugu
  orcidid: 0000-0001-8942-0869
  surname: Miyazaki
  fullname: Miyazaki, Yoshitsugu
  organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan
– sequence: 9
  givenname: Sho
  surname: Ogura
  fullname: Ogura, Sho
  organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
– sequence: 10
  givenname: Takashi
  surname: Sakoh
  fullname: Sakoh, Takashi
  organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
– sequence: 11
  givenname: Takashi
  surname: Mitsuki
  fullname: Mitsuki, Takashi
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 12
  givenname: Kyosuke
  surname: Yamaguchi
  fullname: Yamaguchi, Kyosuke
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 13
  givenname: Mitsuhiro
  surname: Yuasa
  fullname: Yuasa, Mitsuhiro
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 14
  givenname: Daisuke
  surname: Kaji
  fullname: Kaji, Daisuke
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 15
  givenname: Kosei
  surname: Kageyama
  fullname: Kageyama, Kosei
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 16
  givenname: Aya
  surname: Nishida
  fullname: Nishida, Aya
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 17
  givenname: Yuki
  surname: Taya
  fullname: Taya, Yuki
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 18
  givenname: Kazuya
  surname: Ishiwata
  fullname: Ishiwata, Kazuya
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 19
  givenname: Shinsuke
  surname: Takagi
  fullname: Takagi, Shinsuke
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 20
  givenname: Hisashi
  surname: Yamamoto
  fullname: Yamamoto, Hisashi
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 21
  givenname: Go
  surname: Yamamoto
  fullname: Yamamoto, Go
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan
– sequence: 22
  givenname: Naoyuki
  surname: Uchida
  fullname: Uchida, Naoyuki
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
– sequence: 23
  givenname: Atsushi
  surname: Wake
  fullname: Wake, Atsushi
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
– sequence: 24
  givenname: Shuichi
  surname: Taniguchi
  fullname: Taniguchi, Shuichi
  organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
– sequence: 25
  givenname: Hideki
  orcidid: 0000-0002-3349-9296
  surname: Araoka
  fullname: Araoka, Hideki
  organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34780271$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtv1DAUhS1URKeFHWvkJUhNazsvZ4MUhUcrFYFKWVs3yZ2pK8dObc9I_UH8z3pmWgQIVpavv3N8rs4RObDOIiGvOTvlXMiztu1OGa9ylgn-jCw4a2RWlU11QBaMVVVWSFYckqMQblm6lw17QQ7zopZM1HxBfnZGWz2AoWBH-kUP3vXaGbfazbob8DBE9DpEPQTqlvSbdxu09MJuIOgN0jbM6FfaGBd0oB_WSKOjV-DxrPP3c1LR7zMOGgPVlrYJW6HFND3HCaKbncYdE3GiHRpDrz3YMBuwkV4l3azRxvCSPF-CCfjq8TwmPz59vO7Os8uvny-69jKDQhYxq3jf5GXBSjaIsejrpodSctEwDn1d8brvq2pkjYC6ycW4zEGyno1jKXAphcQmPybv977zup9wHNLfHoyavZ7A3ysHWv35YvWNWrmNknVV5iJPBm8fDby7W2OIatJhSHuBRbcOSpSNZHVZ1zyh7_YohEmoW7f2Nq2mOFPbWlWqVe1qVWLLvvk9169ATz0mQOyB1F8IHpdq0BGidtuY2vzP9eQv0ZPvP_EHL-rBCA
CitedBy_id crossref_primary_10_1128_cmr_00015_23
crossref_primary_10_1128_aac_02206_21
crossref_primary_10_1128_aac_02368_21
crossref_primary_10_3390_jof9060628
crossref_primary_10_1128_cmr_00099_22
Cites_doi 10.1016/j.ijid.2012.09.004
10.1128/JCM.00535-08
10.1007/s11046-014-9775-z
10.1128/EC.4.3.625-632.2005
10.1016/j.simyco.2020.05.002
10.1128/AAC.00383-13
10.1016/j.jiac.2018.10.016
10.1093/cid/ciy859
10.1200/JCO.18.00374
10.1128/JCM.01070-09
10.1128/JCM.02023-18
10.1111/myc.13158
10.3201/eid2009.140142
10.1128/AAC.05394-11
10.1378/chest.126.6.1783
10.1086/651263
10.1128/JCM.01582-14
10.1093/mmy/myx067
10.3389/fmicb.2018.01656
10.1093/cid/ciz1008
10.1182/blood-2005-02-0733
10.1093/jac/dkq279
10.1128/AAC.00692-10
ContentType Journal Article
Copyright Copyright © 2022 American Society for Microbiology.
Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology
Copyright_xml – notice: Copyright © 2022 American Society for Microbiology.
– notice: Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.1128/AAC.01630-21
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1098-6596
ExternalDocumentID PMC8765323
01630-21
34780271
10_1128_AAC_01630_21
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP21fk0108094
  funderid: https://doi.org/10.13039/100009619
– fundername: ;
  grantid: JP21fk0108094
GroupedDBID ---
.55
0R~
23M
2WC
39C
4.4
53G
5GY
5RE
5VS
6J9
AAGFI
AAYXX
ACGFO
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CITATION
CS3
DIK
E3Z
EBS
F5P
FRP
GX1
H13
HH5
HYE
HZ~
H~9
K-O
KQ8
L7B
LSO
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UHB
W2D
W8F
WH7
WOQ
X7M
NPM
RHF
-
0R
55
AAPBV
ABFLS
ADACO
BXI
HZ
ZA5
7X8
5PM
ID FETCH-LOGICAL-a484t-61b9354050c2d4b79ba5812901ab7617bb66d092a7932df3a80b0dd52ef828e93
ISSN 0066-4804
1098-6596
IngestDate Thu Aug 21 13:46:45 EDT 2025
Fri Jul 11 09:51:25 EDT 2025
Tue Jan 18 18:30:17 EST 2022
Thu Jan 02 22:54:43 EST 2025
Thu Apr 24 23:05:23 EDT 2025
Tue Jul 01 04:13:26 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords rare species
invasive aspergillosis
allogeneic hematopoietic stem cell transplant recipients
proven invasive aspergillosis
cryptic species
Language English
License All Rights Reserved. https://doi.org/10.1128/ASMCopyrightv2
All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a484t-61b9354050c2d4b79ba5812901ab7617bb66d092a7932df3a80b0dd52ef828e93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors declare no conflict of interest.
ORCID 0000-0002-6635-4288
0000-0003-4461-1500
0000-0002-3987-9118
0000-0002-3349-9296
0000-0001-8942-0869
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/8765323
PMID 34780271
PQID 2598075771
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8765323
proquest_miscellaneous_2598075771
asm2_journals_10_1128_AAC_01630_21
pubmed_primary_34780271
crossref_citationtrail_10_1128_AAC_01630_21
crossref_primary_10_1128_AAC_01630_21
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20220118
PublicationDateYYYYMMDD 2022-01-18
PublicationDate_xml – month: 1
  year: 2022
  text: 20220118
  day: 18
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Antimicrobial agents and chemotherapy
PublicationTitleAbbrev Antimicrob Agents Chemother
PublicationTitleAlternate Antimicrob Agents Chemother
PublicationYear 2022
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
Anonymous (e_1_3_3_12_2) 2008
e_1_3_3_17_2
e_1_3_3_9_2
e_1_3_3_16_2
e_1_3_3_19_2
e_1_3_3_18_2
e_1_3_3_13_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_15_2
e_1_3_3_14_2
e_1_3_3_25_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_4_2
e_1_3_3_11_2
e_1_3_3_22_2
e_1_3_3_3_2
e_1_3_3_10_2
e_1_3_3_21_2
Houbraken, J, Kocsube, S, Visagie, CM, Yilmaz, N, Wang, XC, Meijer, M, Kraak, B, Hubka, V, Bensch, K, Samson, RA, Frisvad, JC (B2) 2020; 95
Racil, Z, Weinbergerova, B, Kocmanova, I, Muzik, J, Kouba, M, Drgona, L, Masarova, L, Guman, T, Tothova, E, Forsterova, K, Haber, J, Ziakova, B, Bojtarova, E, Vydra, J, Mudry, P, Foralova, R, Sejnova, D, Mallatova, N, Kandrnal, V, Cetkovsky, P, Mayer, J (B19) 2013; 17
Tsang, CC, Tang, JYM, Ye, H, Xing, F, Lo, SKF, Xiao, C, Han, L, Wu, AKL, Ngan, AHY, Law, KC, To, YN, Sze, DTT, Chim, OHY, Hui, TWS, Leung, CWH, Zhu, T, Yao, C, Tse, BPH, Lau, SKP, Woo, PCY (B4) 2020; 63
Negri, CE, Goncalves, SS, Xafranski, H, Bergamasco, MD, Aquino, VR, Castro, PT, Colombo, AL (B5) 2014; 52
Pinto, E, Monteiro, C, Maia, M, Faria, MA, Lopes, V, Lameiras, C, Pinheiro, D (B14) 2018; 9
Pfaller, MA, Messer, SA, Boyken, L, Rice, C, Tendolkar, S, Hollis, RJ, Diekema, DJ (B24) 2008; 46
Balajee, SA, Kano, R, Baddley, JW, Moser, SA, Marr, KA, Alexander, BD, Andes, D, Kontoyiannis, DP, Perrone, G, Peterson, S, Brandt, ME, Pappas, PG, Chiller, T (B3) 2009; 47
Alastruey-Izquierdo, A, Alcazar-Fuoli, L, Cuenca-Estrella, M (B7) 2014; 178
Bueid, A, Howard, SJ, Moore, CB, Richardson, MD, Harrison, E, Bowyer, P, Denning, DW (B15) 2010; 65
Kontoyiannis, DP, Marr, KA, Park, BJ, Alexander, BD, Anaissie, EJ, Walsh, TJ, Ito, J, Andes, DR, Baddley, JW, Brown, JM, Brumble, LM, Freifeld, AG, Hadley, S, Herwaldt, LA, Kauffman, CA, Knapp, K, Lyon, GM, Morrison, VA, Papanicolaou, G, Patterson, TF, Perl, TM, Schuster, MG, Walker, R, Wannemuehler, KA, Wingard, JR, Chiller, TM, Pappas, PG (B1) 2010; 50
Yamairi, K, Ido, K, Nakamura, S, Niki, M, Imoto, W, Shibata, W, Namikawa, H, Fujimoto, H, Yamada, K, Nakamae, H, Hino, M, Kaneko, Y, Miyazaki, Y, Kakeya, H (B8) 2019; 25
Alastruey-Izquierdo, A, Mellado, E, Pelaez, T, Peman, J, Zapico, S, Alvarez, M, Rodriguez-Tudela, JL, Cuenca-Estrella, M, Group, FS (B13) 2013; 57
(B11) 2008
Lestrade, PP, Bentvelsen, RG, Schauwvlieghe, A, Schalekamp, S, van der Velden, W, Kuiper, EJ, van Paassen, J, van der Hoven, B, van der Lee, HA, Melchers, WJG, de Haan, AF, van der Hoeven, HL, Rijnders, BJA, van der Beek, MT, Verweij, PE (B22) 2019; 68
Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, BJ, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z (B9) 2020; 71
Cho, SY, Lee, DG, Kim, WB, Chun, HS, Park, C, Myong, JP, Park, YJ, Choi, JK, Lee, HJ, Kim, SH, Park, SH, Choi, SM, Choi, JH, Yoo, JH (B12) 2019; 57
Pham, CD, Reiss, E, Hagen, F, Meis, JF, Lockhart, SR (B17) 2014; 20
Matt, P, Bernet, F, Habicht, J, Gambazzi, F, Gratwohl, A, Zerkowski, HR, Tamm, M (B21) 2004; 126
Schwartz, S, Ruhnke, M, Ribaud, P, Corey, L, Driscoll, T, Cornely, OA, Schuler, U, Lutsar, I, Troke, P, Thiel, E (B20) 2005; 106
Mortensen, KL, Mellado, E, Lass-Florl, C, Rodriguez-Tudela, JL, Johansen, HK, Arendrup, MC (B16) 2010; 54
Taplitz, RA, Kennedy, EB, Bow, EJ, Crews, J, Gleason, C, Hawley, DK, Langston, AA, Nastoupil, LJ, Rajotte, M, Rolston, KV, Strasfeld, L, Flowers, CR (B23) 2018; 36
Balajee, SA, Gribskov, JL, Hanley, E, Nickle, D, Marr, KA (B10) 2005; 4
Tashiro, M, Izumikawa, K, Minematsu, A, Hirano, K, Iwanaga, N, Ide, S, Mihara, T, Hosogaya, N, Takazono, T, Morinaga, Y, Nakamura, S, Kurihara, S, Imamura, Y, Miyazaki, T, Nishino, T, Tsukamoto, M, Kakeya, H, Yamamoto, Y, Yanagihara, K, Yasuoka, A, Tashiro, T, Kohno, S (B18) 2012; 56
Won, EJ, Shin, JH, Kim, SH, Choi, MJ, Byun, SA, Kim, MN, Lee, WG, Lee, K, Uh, Y, Shin, MG, Suh, SP (B6) 2018; 56
References_xml – ident: e_1_3_3_20_2
  doi: 10.1016/j.ijid.2012.09.004
– ident: e_1_3_3_25_2
  doi: 10.1128/JCM.00535-08
– ident: e_1_3_3_8_2
  doi: 10.1007/s11046-014-9775-z
– ident: e_1_3_3_11_2
  doi: 10.1128/EC.4.3.625-632.2005
– ident: e_1_3_3_3_2
  doi: 10.1016/j.simyco.2020.05.002
– ident: e_1_3_3_14_2
  doi: 10.1128/AAC.00383-13
– ident: e_1_3_3_9_2
  doi: 10.1016/j.jiac.2018.10.016
– ident: e_1_3_3_23_2
  doi: 10.1093/cid/ciy859
– ident: e_1_3_3_24_2
  doi: 10.1200/JCO.18.00374
– ident: e_1_3_3_4_2
  doi: 10.1128/JCM.01070-09
– ident: e_1_3_3_13_2
  doi: 10.1128/JCM.02023-18
– ident: e_1_3_3_5_2
  doi: 10.1111/myc.13158
– ident: e_1_3_3_18_2
  doi: 10.3201/eid2009.140142
– ident: e_1_3_3_19_2
  doi: 10.1128/AAC.05394-11
– ident: e_1_3_3_22_2
  doi: 10.1378/chest.126.6.1783
– ident: e_1_3_3_2_2
  doi: 10.1086/651263
– ident: e_1_3_3_6_2
  doi: 10.1128/JCM.01582-14
– ident: e_1_3_3_7_2
  doi: 10.1093/mmy/myx067
– ident: e_1_3_3_15_2
  doi: 10.3389/fmicb.2018.01656
– ident: e_1_3_3_10_2
  doi: 10.1093/cid/ciz1008
– volume-title: CLSI. reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard
  year: 2008
  ident: e_1_3_3_12_2
– ident: e_1_3_3_21_2
  doi: 10.1182/blood-2005-02-0733
– ident: e_1_3_3_16_2
  doi: 10.1093/jac/dkq279
– ident: e_1_3_3_17_2
  doi: 10.1128/AAC.00692-10
– volume: 50
  start-page: 1091
  year: 2010
  end-page: 1100
  ident: B1
  article-title: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database
  publication-title: Clin Infect Dis
  doi: 10.1086/651263
– volume: 95
  start-page: 5
  year: 2020
  end-page: 169
  ident: B2
  article-title: Classification of Aspergillus, Penicillium, Talaromyces and related genera (Eurotiales): an overview of families, genera, subgenera, sections, series and species
  publication-title: Stud Mycol
  doi: 10.1016/j.simyco.2020.05.002
– volume: 36
  start-page: 3043
  year: 2018
  end-page: 3054
  ident: B23
  article-title: Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.00374
– volume: 54
  start-page: 4545
  year: 2010
  end-page: 4549
  ident: B16
  article-title: Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00692-10
– volume: 20
  start-page: 1498
  year: 2014
  end-page: 1503
  ident: B17
  article-title: Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011–2013
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2009.140142
– volume: 71
  start-page: 1367
  year: 2020
  end-page: 1376
  ident: B9
  article-title: Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz1008
– volume: 57
  year: 2019
  ident: B12
  article-title: Epidemiology and antifungal susceptibility profile of Aspergillus species: comparison between environmental and clinical isolates from patients with hematologic malignancies
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.02023-18
– volume: 17
  start-page: e101
  year: 2013
  end-page: 109
  ident: B19
  article-title: Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2012.09.004
– volume: 68
  start-page: 1463
  year: 2019
  end-page: 1471
  ident: B22
  article-title: Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciy859
– volume: 126
  start-page: 1783
  year: 2004
  end-page: 1788
  ident: B21
  article-title: Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia
  publication-title: Chest
  doi: 10.1378/chest.126.6.1783
– volume: 46
  start-page: 2568
  year: 2008
  end-page: 2572
  ident: B24
  article-title: In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00535-08
– volume: 57
  start-page: 3380
  year: 2013
  end-page: 3387
  ident: B13
  article-title: Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00383-13
– volume: 52
  start-page: 3633
  year: 2014
  end-page: 3640
  ident: B5
  article-title: Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01582-14
– volume: 47
  start-page: 3138
  year: 2009
  end-page: 3141
  ident: B3
  article-title: Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01070-09
– volume: 178
  start-page: 427
  year: 2014
  end-page: 433
  ident: B7
  article-title: Antifungal susceptibility profile of cryptic species of Aspergillus
  publication-title: Mycopathologia
  doi: 10.1007/s11046-014-9775-z
– year: 2008
  ident: B11
  publication-title: CLSI. reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard ;(2nd ed) ;CLSI document M38-A2 ;Clinical and Laboratory Standards Institute, Wayne, PA
– volume: 9
  start-page: 1656
  year: 2018
  ident: B14
  article-title: Aspergillus species and antifungals susceptibility in clinical setting in the north of Portugal: cryptic species and emerging azoles resistance in A. fumigatus
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2018.01656
– volume: 56
  start-page: 501
  year: 2018
  end-page: 505
  ident: B6
  article-title: Antifungal susceptibilities to amphotericin B, triazoles and echinocandins of 77 clinical isolates of cryptic Aspergillus species in multicenter surveillance in Korea
  publication-title: Med Mycol
  doi: 10.1093/mmy/myx067
– volume: 25
  start-page: 307
  year: 2019
  end-page: 310
  ident: B8
  article-title: Successful treatment of invasive pulmonary aspergillosis caused by Aspergillus felis, a cryptic species within the Aspergillus section Fumigati: A case report
  publication-title: J Infect Chemother
  doi: 10.1016/j.jiac.2018.10.016
– volume: 56
  start-page: 584
  year: 2012
  end-page: 587
  ident: B18
  article-title: Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.05394-11
– volume: 4
  start-page: 625
  year: 2005
  end-page: 632
  ident: B10
  article-title: Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus
  publication-title: Eukaryot Cell
  doi: 10.1128/EC.4.3.625-632.2005
– volume: 106
  start-page: 2641
  year: 2005
  end-page: 2645
  ident: B20
  article-title: Improved outcome in central nervous system aspergillosis, using voriconazole treatment
  publication-title: Blood
  doi: 10.1182/blood-2005-02-0733
– volume: 65
  start-page: 2116
  year: 2010
  end-page: 2118
  ident: B15
  article-title: Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkq279
– volume: 63
  start-page: 1283
  year: 2020
  end-page: 1298
  ident: B4
  article-title: Rare/cryptic Aspergillus species infections and importance of antifungal susceptibility testing
  publication-title: Mycoses
  doi: 10.1111/myc.13158
SSID ssj0006590
Score 2.423076
Snippet There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant...
SourceID pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0163021
SubjectTerms Epidemiology and Surveillance
Mycology
Title Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients
URI https://www.ncbi.nlm.nih.gov/pubmed/34780271
https://journals.asm.org/doi/10.1128/AAC.01630-21
https://www.proquest.com/docview/2598075771
https://pubmed.ncbi.nlm.nih.gov/PMC8765323
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGEIgXBOU2bjII9rJlS537Y1WYJqaiMXXS9hTZibtGa5OqSR7K_-H38Jc4x86tHZMGL1FlH6Vuzxf72Dnfdwj55Lix23edvmFxuNgQ0RpiYgZGJExvgpJatkC-8-i7e3xuf7twLra2fneylspCHEQ__8or-R-vQhv4FVmy_-DZ5qbQAJ_Bv3AFD8P1Tj4e1rRGlS2RNJpKqm24IcWMyW7LDOY21NbgKmt9gDLhV8lslqEsyZdSldE443gsfTRcrhYo5qoK1Kusrb0BGMJYJLQeo9RrtsgSqWwKOd8b4img1kqfgbswIE0WSS0V1SjdpkUy1yPFcV8pgp3i1k3lvGKDNaf8l3zO5xUT52yV5eV1A8OTBDpU4DsqUwl906TBbs7TzBhlmkN_WV63PUKfw_OcT5Nl1j3xYJg6YlSTdEsywNmvk9fa-Y-7UygEVIbt6wLHB1JP8aig6jq6jm69BujKL12s31xaGNIlBoPhAUTJlmloYveGWHfddY_cZ7BvwZIaJz9a-Xr4Ws2JqoZVMzGYf9i9MYQHPJ-z9VDpxv5nM423ExeNn5DH1YaGDjQ6n5ItmfbIA13idNUjD0dV8kaP7J5qmfTVPh23rL98n-7S01ZAffWM_KpxTQEYdAPXdAPXNJtQjWta45qu4ZoCrmmRUcT1YYVqWqGaJiltUU3XUE0R1RRRTVtU0xbVz8n50dfx8NioyokY3PbtwnD7IsBTTseMWGwLLxDc8fEYts-FB4G8EK4bmwHjsGSxeGJx3xRmHDtMTnzmy8B6QbbTLJWvCGUmdwMrEIrDIyeW7_kRE1HkxNLuRzzYIR_RgWE1V-Sh2mozPwQvh8rLIevvkL3avWFUCfJjXZjZLdafG-uFFqK5xe5DjZQQVgp8_cdTmZV5yJwAlcc9D2xeauQ0d7JszzcZ9nhrmGoMUIV-vSdNpkqNHsIpx2LW67v85DfkUftAvyXbxbKU7yCoL8R79aD8AaiS_pQ
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+and+Microbiological+Characteristics+of+Proven+Invasive+Aspergillosis+Due+to+Rare%2FCryptic+Species+in+Allogeneic+Hematopoietic+Stem+Cell+Transplant+Recipients&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Yamamuro%2C+Ryosuke&rft.au=Kimura%2C+Muneyoshi&rft.au=Asano-Mori%2C+Yuki&rft.au=Abe%2C+Masahiro&rft.date=2022-01-18&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=66&rft.issue=1&rft_id=info:doi/10.1128%2FAAC.01630-21&rft.externalDocID=01630-21
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon